Sellas Life Sciences Group (SLS) said Sunday that results of an ongoing phase 2 study of SLS009 in combination with azacitidine and venetoclax showed "clinically meaningful" activity in patients with relapsed or refractory acute myeloid leukemia, a type of cancer.

Among the 35 evaluable patients, the overall response rate was 46%. Patients harboring ASXL1 or TP53 mutations achieved response rates of 48% and 57%, respectively. The company said the median overall survival was "exceedingly higher" than the expected 2.6 months in this patient population.

The results didn't show any dose-limiting toxicities or treatment-related deaths, and the combination was well tolerated, according to Sellas.

The company's shares were up 8.1% in recent premarket activity Monday.